Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 9« First...34567...Last »

Medtronic settles states’ probe into Infuse marketing for $12 million

Medtronic Plc agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said.

Read More »

Regeneron, Sanofi Show Off Phase II Skin Cancer Data

Impressive top-line results were reported from a pivotal Phase II study for the PD-1 inhibitor cemiplimab.

Read More »

Daichi Sankyo Abandons Deal With Nektar Therapeutics After Drug Tanks in Europe

Daiichi Sankyo Europe GmbH informed Nektar Therapeutics that it was terminating a collaboration and licensing deal, which becomes effective Feb. 4, 2018. All rights and licenses that Daiichi acquired in the deal will revert to Nektar.

Read More »

J&J Tops Bioethics International Transparency Report

Johnson & Johnson topped the Bioethics International “Good Pharma Scorecard” for the second year in a row.

Read More »

Half of world’s people can’t get basic health services: WHO

At least half the world’s population is unable to access essential health services and many others are forced into extreme poverty by having to pay for healthcare they cannot afford, the World Health Organization said.

Read More »

Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020

Eli Lilly and Company today announced its 2018 financial guidance, including low-single-digit revenue growth driven by volume from recently launched pharmaceutical products. The company also highlighted key events for 2018, including continued progress on Lilly’s pipeline.

Read More »

Sanofi pins hopes on new drugs after setbacks

Sanofi management expressed confidence that the company’s pipeline of new products will support long-term growth.

Read More »

Republicans propose to delay, pause Obamacare taxes

U.S. House Republicans proposed to delay or suspend several taxes under former President Barack Obama’s healthcare law, including a tax on medical devices and the so-called “Cadillac” tax on generous health insurance plans.

Read More »

Allergan Swoops in and Bags Troubled Repros Therapeutics

Allergan is buying Repros Therapeutics for $0.67 per share. The deal is expected to close in the first quarter of 2018.

Read More »

265 Employees Affected as San Diego’s Dart NeuroScience Decides to Close Its Doors

Privately held Dart NeuroScience and its quest to develop therapies intended to improve cognitive vitality will close its doors on Feb. 9, 2018, due to poor progress on the San Diego-based company’s therapeutic goals and little return on hundreds of millions of dollars in research and development.

Read More »

U.S. FDA accepts application for Indivior’s new schizophrenia drug

The FDA accepted Indivior’s application for its new once-monthly injectable schizophrenia treatment.

Read More »

FDA proposes new fast path to market for certain medical devices

The U.S. Food and Drug Administration proposed creating a new fast track to market for certain medical devices and a potential reduction in the amount of safety data required for approval.

Read More »

Kyprolis improves overall survival in blood cancer

Amgen Inc. said a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Read More »

Promising responses seen with Agios leukemia drug in study

Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early-stage trial.

Read More »

FDA OKs Sanofi follow-on biologic

The U.S. Food and Drug Administration approved Sanofi SA’s Admelog as the first follow-on biologic version of Eli Lilly and Co.’s fast-acting insulin Humalog.

Read More »

Genentech’s Hemlibra Data Wows at ASH

At the American Society of Hematology meeting, Genentech revealed long-term data showing the drug maintains its efficacy over an extended period of time.

Read More »

bluebird, Celgene Tout ‘Unheard of’ Early-Stage Multiple Myeloma Data

Summit, NJ-based Celgene and Cambridge, Mass.-based bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the American Society of Hematology (ASH) Annual Meeting in Atlanta.

Read More »

‘Ground-breaking’ new drug gives hope in Huntington’s disease

Scientists have for the first time fixed a protein defect that causes Huntington’s disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

Read More »

Verastem Announces Pivotal Clinical Data

The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.

Read More »

PhRMA sues to stop California drug price law

The trade group representing U.S. drugmakers filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices.

Read More »

Page 5 of 9« First...34567...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation